Module

Adjuvant and Neoadjuvant Therapy for Early-Stage NSCLC

Source: Research Priorities in Non-Small-Cell Lung Cancer

Adjuvant and Neoadjuvant Therapy for Early-Stage NSCLC

Faculty:
Paul A. Bunn, Jr., MD

CME CREDIT INFORMATION

Release Date: 03/14/07

Expiration Date: 03/13/08

Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Review the use of adjuvant and neoadjuvant therapy in the setting of NSCLC
Discuss reasons for low enrollment in lung cancer clinical trials
Summarize the use of epidermal growth factor receptor tyrosine kinase inhibitors in patients with NSCLC

Topics covered include:

Introduction
Adjuvant and Neoadjuvant Chemotherapy
Targeted Therapies
Priority Trials in Early-Stage NSCLC
Treatment of Locally Advanced NSCLC
Optimizing Radiation Therapy and Chemotherapy
Integration of Molecularly Targeted Therapies
Priority Trials in Locally Advanced NSCLC
Conclusion

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.